Royalty Report: Drugs, Cancer, Therapeutic – Collection: 26784


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26784

License Grant
The Licensee will receive the exclusive right to market, distribute and sell the Products in the Territory.  If Licensee has not enrolled at least 20 patients in a controlled, mutually designed head & neck cancer clinical trial by June 1, 2004, they will lose the exclusive right to market, distribute and sell the Products in the Territory.  Licensee may market, sell and/or distribute the Products under the trademark owned or used by the Company (e.g. Multikine(TM)).
License Property
MultikineTM is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines including Interleukins, interferons, chemokines and colony-stimulating factors.  As a neo-adjuvant, Multikine has induced tumor reduction and tumor necrosis in Phase II trials of head & neck cancer.  Multikine is nontoxic and offers a diverse and possibly synergistic cytokine profile believed to play an important role in local and regional and possible systemic immune restoration.

MULTIKINE(R) is manufactured using proprietary cell culture technologies, is a combination, or 'cocktail', of natural human interleukin-2 ('IL-2') and certain lymphokines and cytokines. MULTIKINE is being tested to determine if it is effective in improving the immune response of cancer patients.

Field of Use
Multikine appears to boost the patient’s immune system and break tumor tolerance.  The CEL-1000 is a peptide that has been shown to provide protection in animals against malaria, herpes and cancer.

IPSCIO Record ID: 27362

License Grant
In 1983, the Company acquired the exclusive worldwide rights to patented IL-2 compounds, compositions and other processes and other lymphokine – related compounds, compositions and processes one of which is sometimes referred to as Multikinetm, or buffy-coat interleukins, which is a combination, or cocktail of IL-2 and certain lymphokines and cytokines.  Multikine is a natural mixture of human immune system regulators called cytokines, including Interleukin-2 and others.  Several are being investigated individually as potential HIV-1 and cancer treatments.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 28194

License Grant
These three Agreements all relate to an overall Agreement for the Licensee and the European Licensor to work jointly on the clinical development of Multikine.

The Licensee will have the right to conduct the clinical development of, as well as the commercialization and intellectual property maintenance for Multikine and will bear all associated costs for these activities.

License Property
The Licensor is a clinical development company providing consultancy and full clinical trial related services.
Field of Use
The Licensee's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is currently being developed as a potential neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. The Licensee will have primary responsibility for new patient enrollment in the Phase 3 clinical trial.

IPSCIO Record ID: 415

License Grant
The Company acquired the intellectual property rights relating to certain combination immunogene therapy technology.
License Property
The technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025.  The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells.  The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF.  Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 246211

License Grant
The Licensor hereby grants to the Licensee an exclusive, worldwide, royalty-bearing license under Licensors rights in the Licensed Technology to make, develop, use, sell, offer for sale and import Licensed Products in the Field. Such license shall include the right to grant sublicenses. The IP is a proprietary biological molecule that inhibits soluble tumor necrosis factor.
License Property
The Licensor has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor.

INB03 is a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells.

Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.

Field of Use
Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.